Reports Q3 revenue $10.79M, consensus $9.32M. “Our third quarter was marked by significant progress across our pipeline and important data releases, particularly the impressive interim antiviral activity and clinical outcomes data from our Phase 1b study for ABI-5366 in participants with recurrent genital herpes,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “The $175 million equity investment we completed in August enables us to advance both our HSV and HDV programs into Phase 2 while continuing our efforts to discover and develop new programs. With enrollment in our Phase 1b study for ABI-5366 and two cohorts in our Phase 1b study for ABI-1179 now complete, we look forward to sharing additional data updates from our HSV program later this year.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASMB:
- Assembly Biosciences announces Phase 1b data for ABI-4334
- ASMB Earnings this Week: How Will it Perform?
- Assembly Biosciences Advances HSV-2 Treatment Study with ABI-1179
- Assembly Biosciences’ Promising HSV-2 Treatment Study: Key Insights for Investors
- Assembly Biosciences’ ABI-6250 Study: A Potential Game-Changer in Hepatitis Treatment